BMS-929075 is a HCV NS5B Replicase Palm Site Allosteric Inhibitor. BMS-929075 exhibited a favorable cytotoxicity window. BMS-929075 demonstrated efficacy in a triple combination regimen in HCV replicon cells, and exhibited consistently high orally bioavailable bioavailability and pharmacokinetic parameters across preclinical animal species. The human PK properties from the Phase I clinical studies of BMS-929075 were better than anticipated and suggested promising potential for QD administration. References: Yeung KS, Beno BR, Parcella K, Bender JA, Grant-Young KA, Nickel A, Gunaga P, Anjanappa P, Bora RO, Selvakumar K, Rigat K, Wang YK, Liu M, Lemm JA, Mosure K, Sheriff S, Wan C, Witmer M, Kish K, Hanumegowda UM, Zhuo X, Shu YZ, Parker D, Haskell R, Ng A, Gao Q, Colston E, Raybon J, Grasela DM, Santone KS, Gao M, Meanwell NA, Sinz MW, Soars MG, Knipe JO, Roberts SB, Kadow JF. Discovery of an HCV NS5B Replicase Palm Site Allosteric Inhibitor (BMS-929075) Advanced to Phase 1 Clinical Studies. J Med Chem. 2017 Apr 21. doi: 10.1021/acs.jmedchem.7b00328. [Epub ahead of print] PubMed PMID: 28430437.

纯度：≥98%

CAS：1217338-97-0